IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS • PTIBS0AM0008

11.4 EUR
+0.1 (+0.88%)
Last: Feb 24, 2026, 05:27 PM
Fundamental Rating

4

Overall IBS gets a fundamental rating of 4 out of 10. We evaluated IBS against 57 industry peers in the Hotels, Restaurants & Leisure industry. IBS has an average financial health and profitability rating. IBS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year IBS was profitable.
  • IBS had a positive operating cash flow in the past year.
  • Of the past 5 years IBS 4 years were profitable.
  • In the past 5 years IBS always reported a positive cash flow from operatings.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • The Return On Assets of IBS (1.91%) is worse than 61.40% of its industry peers.
  • IBS's Return On Equity of 4.21% is in line compared to the rest of the industry. IBS outperforms 56.14% of its industry peers.
  • With a Return On Invested Capital value of 4.53%, IBS perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for IBS is significantly below the industry average of 11.95%.
  • The last Return On Invested Capital (4.53%) for IBS is above the 3 year average (3.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROIC 4.53%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • IBS has a Profit Margin of 2.56%. This is comparable to the rest of the industry: IBS outperforms 40.35% of its industry peers.
  • IBS's Profit Margin has declined in the last couple of years.
  • IBS has a Operating Margin (5.83%) which is in line with its industry peers.
  • In the last couple of years the Operating Margin of IBS has declined.
  • IBS's Gross Margin of 52.62% is in line compared to the rest of the industry. IBS outperforms 56.14% of its industry peers.
  • In the last couple of years the Gross Margin of IBS has remained more or less at the same level.
Industry RankSector Rank
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IBS is destroying value.
  • IBS has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IBS has more shares outstanding
  • IBS has a worse debt/assets ratio than last year.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 2.17 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • IBS's Altman-Z score of 2.17 is fine compared to the rest of the industry. IBS outperforms 63.16% of its industry peers.
  • The Debt to FCF ratio of IBS is 3.47, which is a good value as it means it would take IBS, 3.47 years of fcf income to pay off all of its debts.
  • IBS's Debt to FCF ratio of 3.47 is fine compared to the rest of the industry. IBS outperforms 71.93% of its industry peers.
  • IBS has a Debt/Equity ratio of 0.66. This is a neutral value indicating IBS is somewhat dependend on debt financing.
  • IBS's Debt to Equity ratio of 0.66 is fine compared to the rest of the industry. IBS outperforms 73.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Altman-Z 2.17
ROIC/WACC0.72
WACC6.3%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.02 indicates that IBS should not have too much problems paying its short term obligations.
  • With a decent Current ratio value of 1.02, IBS is doing good in the industry, outperforming 64.91% of the companies in the same industry.
  • A Quick Ratio of 0.92 indicates that IBS may have some problems paying its short term obligations.
  • The Quick ratio of IBS (0.92) is better than 61.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.92
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

4

3. Growth

3.1 Past

  • IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.66%.
  • The Earnings Per Share has been decreasing by -8.23% on average over the past years.
  • IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.02%.
  • Measured over the past years, IBS shows a decrease in Revenue. The Revenue has been decreasing by -0.46% on average per year.
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%

3.2 Future

  • Based on estimates for the next years, IBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.57% on average per year.
  • The Revenue is expected to grow by 7.42% on average over the next years.
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 33.53, the valuation of IBS can be described as expensive.
  • IBS's Price/Earnings is on the same level as the industry average.
  • IBS's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.64.
  • Based on the Price/Forward Earnings ratio of 36.02, the valuation of IBS can be described as expensive.
  • Based on the Price/Forward Earnings ratio, IBS is valued a bit more expensive than the industry average as 61.40% of the companies are valued more cheaply.
  • IBS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 27.75, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.53
Fwd PE 36.02
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IBS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IBS is cheaper than 84.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.63
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.66%
EPS Next 3Y2.31%

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.28%, IBS is a good candidate for dividend investing.
  • IBS's Dividend Yield is rather good when compared to the industry average which is at 1.28. IBS pays more dividend than 98.25% of the companies in the same industry.
  • IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 6.28%

5.2 History

  • On average, the dividend of IBS grows each year by 48.65%, which is quite nice.
Dividend Growth(5Y)48.65%
Div Incr Years0
Div Non Decr Years0
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • IBS pays out 213.50% of its income as dividend. This is not a sustainable payout ratio.
  • IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP213.5%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

IBERSOL SGPS SA

ELI:IBS (2/24/2026, 5:27:27 PM)

11.4

+0.1 (+0.88%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-27
Earnings (Next)04-27
Inst Owners21.87%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap466.26M
Revenue(TTM)522.73M
Net Income(TTM)13.37M
Analysts83.33
Price Target11.92 (4.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.28%
Yearly Dividend0.49
Dividend Growth(5Y)48.65%
DP213.5%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.41%
Max Revenue beat(2)-0.81%
Revenue beat(4)2
Avg Revenue beat(4)4.87%
Min Revenue beat(4)-3.41%
Max Revenue beat(4)12.41%
Revenue beat(8)6
Avg Revenue beat(8)5.92%
Revenue beat(12)8
Avg Revenue beat(12)5.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-25.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 33.53
Fwd PE 36.02
P/S 0.89
P/FCF 5.63
P/OCF 3.62
P/B 1.47
P/tB 2.13
EV/EBITDA N/A
EPS(TTM)0.34
EY2.98%
EPS(NY)0.32
Fwd EY2.78%
FCF(TTM)2.02
FCFY17.76%
OCF(TTM)3.15
OCFY27.59%
SpS12.78
BVpS7.76
TBVpS5.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.7
Profitability
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROCE 5.74%
ROIC 4.53%
ROICexc 5.96%
ROICexgc 7.87%
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
FCFM 15.84%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
ROICexc(3y)5.24%
ROICexc(5y)N/A
ROICexgc(3y)7.05%
ROICexgc(5y)N/A
ROCE(3y)4.21%
ROCE(5y)N/A
ROICexgc growth 3Y-24.94%
ROICexgc growth 5Y-3.32%
ROICexc growth 3Y-22.88%
ROICexc growth 5Y-3.24%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.77%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 619.36%
Current Ratio 1.02
Quick Ratio 0.92
Altman-Z 2.17
F-Score7
WACC6.3%
ROIC/WACC0.72
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)9.76%
Cap/Sales(5y)11.65%
Profit Quality(3y)200.89%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%
EBIT growth 1Y34.45%
EBIT growth 3Y-20.54%
EBIT growth 5Y-7.19%
EBIT Next Year455.28%
EBIT Next 3Y83.41%
EBIT Next 5Y61.42%
FCF growth 1Y88.1%
FCF growth 3Y-0.14%
FCF growth 5Y-9.32%
OCF growth 1Y61.81%
OCF growth 3Y1.82%
OCF growth 5Y-6.35%

IBERSOL SGPS SA / IBS.LS FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBS.LS.


Can you provide the valuation status for IBERSOL SGPS SA?

ChartMill assigns a valuation rating of 2 / 10 to IBERSOL SGPS SA (IBS.LS). This can be considered as Overvalued.


Can you provide the profitability details for IBERSOL SGPS SA?

IBERSOL SGPS SA (IBS.LS) has a profitability rating of 4 / 10.


What is the financial health of IBERSOL SGPS SA (IBS.LS) stock?

The financial health rating of IBERSOL SGPS SA (IBS.LS) is 5 / 10.


Can you provide the dividend sustainability for IBS stock?

The dividend rating of IBERSOL SGPS SA (IBS.LS) is 6 / 10 and the dividend payout ratio is 213.5%.